Peer-reviewed veterinary case report
Canine fat stem cells slow growth of dog blood cancer cells
By Yasumura Y et al.·2025·School of Veterinary Medicine, Japan·View original on Europe PMC →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Canine adipose-derived mesenchymal stromal cells inhibit the growth of canine hematologic malignancy cell lines.
- Species:
- dog
Plain-English summary
A study found that special cells taken from fat tissue in dogs, called adipose-derived mesenchymal stromal cells (cADSCs), can slow down the growth of certain types of canine lymphoma (a type of cancer) in the lab and in mice. When these cells were mixed with lymphoma cells, they helped kill the cancer cells and stopped them from growing. This suggests that using cADSCs as a treatment could be safe for dogs with chronic intestinal inflammation, as it may not increase the risk of developing hidden lymphomas. More research is needed, but the results are promising for future therapies.
Abstract
<h4>Introduction</h4>Intestinal lymphoma may be latent in some dogs with chronic inflammatory enteropathy. Mesenchymal stromal cells (MSCs) have potential therapeutic applications for refractory chronic inflammatory enteropathy, but their impact on the development of potential intestinal lymphomas has not yet been evaluated. Therefore, this study was performed to investigate the effect of canine adipose-derived MSCs (cADSCs) on the growth of canine lymphoma cell lines to assess the safety of MSC-based therapy in terms of pro- and anti-tumorigenic effects.<h4>Methods</h4>CADSCs were co-cultured with canine lymphoma/leukemia cell lines of various lineages, with or without cell-to-cell contact, to evaluate their effects on proliferation, apoptosis, and cell cycle progression in vitro. Additionally, a bioluminescent canine lymphoma cell line, established through firefly luciferase transduction, was co-injected with varying doses of cADSCs into immunocompromised mice. The growth of canine lymphoma cells was monitored over time in vivo using bioluminescence imaging.<h4>Results</h4>CADSCs inhibited the proliferation of all canine lymphoma/leukemia cell lines in a dose-dependent manner in vitro, under conditions allowing cell-to-cell contact. This inhibition occurred via the induction of apoptosis, G0/G1 phase cell cycle arrest, or both mechanisms. However, these effects were lost when the cells were physically separated using Transwell inserts. In xenotransplantation mouse models, cADSCs dose-dependently inhibited canine lymphoma cell growth and lung metastasis, as indicated by reduced bioluminescence signals.<h4>Conclusions</h4>This study has demonstrated for the first time that cADSCs inhibit the growth of different lineages of canine lymphoma/leukemia cells both in vitro and in vivo. These findings suggest that MSC-based cell therapy could potentially be applied to canine chronic inflammatory enteropathy without increasing the risk of promoting the growth of latent intestinal lymphomas.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Europe PMC: https://europepmc.org/article/MED/39867136